Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines
Author(s) -
Piper Nicolosi,
Elisa M. Ledet,
Shan Yang,
Scott T. Michalski,
Brandy Freschi,
Erin O’Leary,
Edward D. Esplin,
Robert L. Nussbaum,
Oliver Sartor
Publication year - 2019
Publication title -
jama oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 8.846
H-Index - 99
eISSN - 2374-2445
pISSN - 2374-2437
DOI - 10.1001/jamaoncol.2018.6760
Subject(s) - medicine , germline , prostate cancer , genetic testing , germline mutation , medline , oncology , cancer , genetics , mutation , gene , biology , biochemistry
Prostate cancer is the third leading cause of cancer-related death in men in the United States. Although serious, most of these diagnoses are not terminal. Inherited risk for prostate cancer is associated with aggressive disease and poorer outcomes, indicating a critical need for increased genetic screening to identify disease-causing variants that can pinpoint individuals at increased risk for metastatic castration-resistant prostate cancer.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom